Ovid Therapeutics Inc (STU:1OT)

€ 0.9 -0.01 (-1.1%) Market Cap: 65.17 Mil Enterprise Value: 19.49 Mil PE Ratio: 0 PB Ratio: 0.87 GF Score: 54/100

Ovid Therapeutics Inc To Host Research & Development (R&D) Day Transcript
Oct 02, 2023
Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 17, 2023
Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 14, 2022
Ovid Therapeutics Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Ovid Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 10, 2021
Ovid Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021
Ovid Therapeutics Inc and Takeda Pharmaceutical Co Ltd to Discuss Strategic Transaction Call Transcript
Mar 03, 2021
Ovid Therapeutics Inc. - Special Call Transcript
Oct 22, 2020
Ovid Therapeutics Inc. - Special Call Transcript
Aug 25, 2020
Ovid Therapeutics Inc. - Special Call Transcript
Jul 13, 2020
Ovid Therapeutics Inc. - Special Call Transcript
Jun 17, 2020
Ovid Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 04, 2020
Ovid Therapeutics to Discuss Positive Initial Data from Ongoing ENDYMION Trial Call Transcript
Sep 23, 2019
Ovid Therapeutics Inc. - Special Call Transcript
Jun 27, 2019

Ovid Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 17, 2023 / 03:00PM GMT

Release Date Price: €2.7 (+0.75%)

Transcript

Eason Lee

Needham & Company - Analyst

Good morning, everyone. Welcome to our next session here with Ovid Therapeutics. I'm Eason Lee, one of the associates on the biotech research team here at Needham. And it's my pleasure to be hosting Meg Alexander, the Chief Corporate Affairs Officer for the company. We'll be giving a presentation, and I think we'll have some time for Q&A afterwards.

(Conference Instructions) And with that, Meg, let me turn it over to you.

Meg Alexander

Ovid Therapeutics, Inc. - Chief Corporate Affairs Officer

Thank you, Eason. Good morning, everyone. As Eason mentioned, I'm the Chief Strategy and Chief Corporate Affairs Officer. I'm standing in for Jeremy Levin today, our CEO and Chairman, who had a conflict. I'm very excited to give you an update on Ovid as well as our focus on epilepsy.

I should start by saying that we are a publicly traded company, and this presentation will include forward-looking statements. But for those of you who are not familiar with the Ovid's story, I'm very excited to bring you up

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.